GlassScriptPhysician profile
Levi C Short
NPI 1790198448
$1,455.18
in general payments reported to CMS, 2019-2025
22 companies · $330 in 2025
The $330 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $134 · 2021: $76.39 · 2022: $550 · 2023: $214 · 2024: $150 · 2025: $330.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $695.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $694.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $260.21 | 2019-2025 | Tavneos |
| Calliditas Therapeutics US INC. | $173.18 | 2022-2025 | Tarpeyo |
| Opko Pharmaceuticals, LLC | $120.14 | 2019-2023 | Rayaldee |
| Astrazeneca Pharmaceuticals LP | $118.34 | 2019-2023 | Farxiga |
| Novo Nordisk INC | $106.64 | 2023-2025 | Ozempic, Rybelsus |
| Vifor Pharma, INC. | $90.33 | 2019-2024 | Veltassa |
| Alexion Pharmaceuticals, INC. | $76.39 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $74.40 | 2022-2025 | |
| Akebia Therapeutics INC | $72.21 | 2019-2022 | |
| Mallinckrodt Hospital Products INC. | $53.28 | 2022-2023 | Acthar |
| Glaxosmithkline, LLC. | $50.31 | 2022-2025 | Benlysta |
| Aurinia Pharma U.S., INC. | $50.26 | 2022 | |
| Fresenius USA Marketing, INC. | $41.48 | 2019-2024 | Liberty Select Cycler, Nxstage System One |
| Ani Pharmaceuticals, INC. | $24.71 | 2025 | Purified Cortrophin Gel |
| Alnylam Pharmaceuticals INC. | $23.34 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.42 | 2024 | Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $19.12 | 2022 | |
| Kyowa Kirin, INC. | $17.29 | 2024 | Crysvita |
| Ardelyx, INC. | $17.27 | 2024 | Ibsrela |
| Shield Therapeutics INC | $15.49 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $15.02 | 2022 | |
| Novartis Pharmaceuticals Corporation | $14.35 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Levi Short listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.